Abdominal aortic aneurysm medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 22: Line 22:
*** In the absence of other indications for [[beta blocker]]s, the evidence is insufficient to recommend using them routinely for the sole purpose of slowing atherosclerotic aneurysm growth
*** In the absence of other indications for [[beta blocker]]s, the evidence is insufficient to recommend using them routinely for the sole purpose of slowing atherosclerotic aneurysm growth
===Aspirin===
===Aspirin===
The beneficial effects of [[aspirin]] on prevention of [[CAD]] and [[PAD]] outweighs its risk of causing [[bleeding]]
The beneficial effects of [[aspirin]] on prevention of [[CAD]] and [[PAD]] among patients at low to intermediate risk of bleeding likely outweighs its risk of causing [[bleeding]]


==References==
==References==

Revision as of 13:22, 29 October 2012

Abdominal Aortic Aneurysm Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Abdominal Aortic Aneurysm from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Abdominal aortic aneurysm medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Abdominal aortic aneurysm medical therapy

CDC on Abdominal aortic aneurysm medical therapy

Abdominal aortic aneurysm medical therapy in the news

Blogs on Abdominal aortic aneurysm medical therapy

Directions to Hospitals Treating Abdominal aortic aneurysm medical therapy

Risk calculators and risk factors for Abdominal aortic aneurysm medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2] Aarti Narayan, M.B.B.S [3]

Overview

Risk factor modification including smoking cessation, management of hypertension, and lipid lowering are essential in reducing the risk of development and the rate of progression of abdominal aortic aneurysms.

Risk Factor Modification

  • Smoking contributes to formation and rupture of aneurysm and smoking cessation should be encouraged in patients with an abdominal aortic aneurysm and in individuals with family history of abdominal aortic aneurysm
  • Risk factors for atherosclerosis development and progression such as hypertension and hyperlipidemia should be controlled

Medical Therapy

ACE Inhibitors

  • These agents may be administered to control hypertension in patients with

Statins

  • May reduce mortality in patients who have undergone an abdominal aortic aneurysm repair [1]

Beta Blockers

  • May have a beneficial effect on expansion of aneurysm from its effect on reduction of blood pressure. It is used routinely in patients with abdominal aortic aneurysm followed non-operatively [2]
      • Reduce aortic complications in patients with Marfan syndrome
      • Slow progression of AAAs in hypertensive patients
      • In the absence of other indications for beta blockers, the evidence is insufficient to recommend using them routinely for the sole purpose of slowing atherosclerotic aneurysm growth

Aspirin

The beneficial effects of aspirin on prevention of CAD and PAD among patients at low to intermediate risk of bleeding likely outweighs its risk of causing bleeding

References

  1. Kalyanasundaram A, Elmore JR, Manazer JR; et al. (2006). "Simvastatin suppresses experimental aortic aneurysm expansion". Journal of Vascular Surgery. 43 (1): 117–24. doi:10.1016/j.jvs.2005.08.007. PMID 16414398. Unknown parameter |month= ignored (help)
  2. Hirsch AT, Haskal ZJ, Hertzer NR; et al. (2006). "ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation". Circulation. 113 (11): e463–654. doi:10.1161/CIRCULATIONAHA.106.174526. PMID 16549646. Unknown parameter |month= ignored (help)

Template:WH Template:WS